ATE297732T1 - Kombinationstherapie zur behandlung von herzinsuffizienz - Google Patents

Kombinationstherapie zur behandlung von herzinsuffizienz

Info

Publication number
ATE297732T1
ATE297732T1 AT02743321T AT02743321T ATE297732T1 AT E297732 T1 ATE297732 T1 AT E297732T1 AT 02743321 T AT02743321 T AT 02743321T AT 02743321 T AT02743321 T AT 02743321T AT E297732 T1 ATE297732 T1 AT E297732T1
Authority
AT
Austria
Prior art keywords
heart failure
treatment
combination therapy
combination
levosimendan
Prior art date
Application number
AT02743321T
Other languages
English (en)
Inventor
Pentti Poeder
Heimo Haikala
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp filed Critical Orion Corp
Application granted granted Critical
Publication of ATE297732T1 publication Critical patent/ATE297732T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Electrotherapy Devices (AREA)
  • External Artificial Organs (AREA)
  • Laser Surgery Devices (AREA)
AT02743321T 2001-07-04 2002-07-04 Kombinationstherapie zur behandlung von herzinsuffizienz ATE297732T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20011464A FI20011464A0 (fi) 2001-07-04 2001-07-04 Yhdistelmäterapia sydämen vajaatoiminnan hoitoon
PCT/FI2002/000606 WO2003007962A1 (en) 2001-07-04 2002-07-04 A combination therapy for the treatment of heart failure

Publications (1)

Publication Number Publication Date
ATE297732T1 true ATE297732T1 (de) 2005-07-15

Family

ID=8561589

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02743321T ATE297732T1 (de) 2001-07-04 2002-07-04 Kombinationstherapie zur behandlung von herzinsuffizienz

Country Status (10)

Country Link
US (1) US6949548B2 (de)
EP (1) EP1408977B1 (de)
JP (2) JP2004535463A (de)
AT (1) ATE297732T1 (de)
CA (1) CA2450915C (de)
DE (1) DE60204694T2 (de)
ES (1) ES2243740T3 (de)
FI (1) FI20011464A0 (de)
PT (1) PT1408977E (de)
WO (1) WO2003007962A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20011465A0 (fi) * 2001-07-04 2001-07-04 Orion Corp Pyridatsinonijohdannaisen uusi käyttö
CA2492084A1 (en) 2002-06-27 2004-01-08 Sb Pharmco Puerto Rico Inc. Carvedilol hydobromide
AU2003248746B2 (en) 2002-06-27 2009-01-08 Smithkline Beecham (Cork) Limited Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment
JPWO2004087641A1 (ja) * 2003-03-31 2006-06-29 第一製薬株式会社 ヒドラゾン誘導体
US7750036B2 (en) 2003-11-25 2010-07-06 Sb Pharmco Puerto Rico Inc. Carvedilol salts, corresponding compositions, methods of delivery and/or treatment
FI20040674A0 (fi) * 2004-05-12 2004-05-12 Orion Corp Menetelmä tromboembolisten sairauksien estoon
WO2006087420A2 (en) * 2005-02-18 2006-08-24 Orion Corporation A method for treating heart failure
US20080070917A1 (en) * 2005-02-18 2008-03-20 Thakkar Roopal B Methods for administering levosimendan
US20130130869A1 (en) * 2011-11-22 2013-05-23 Kuang-Hua HOU Platform for supporting conveyor belt of treadmill
EP4076398B1 (de) 2019-12-16 2026-02-18 Tenax Therapeutics, Inc. Levosimendan zum behandeln der pulmonalen hypertension bei herzinsuffizienz mit erhaltener auswurffraktion (ph-hf-pef)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2251615B (en) 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile
US5998458A (en) * 1997-06-25 1999-12-07 University Technology Corporation Method of treating heart failure

Also Published As

Publication number Publication date
US20040209885A1 (en) 2004-10-21
FI20011464A0 (fi) 2001-07-04
EP1408977B1 (de) 2005-06-15
EP1408977A1 (de) 2004-04-21
DE60204694D1 (de) 2005-07-21
JP2010065060A (ja) 2010-03-25
PT1408977E (pt) 2005-08-31
WO2003007962A1 (en) 2003-01-30
ES2243740T3 (es) 2005-12-01
CA2450915C (en) 2010-09-28
DE60204694T2 (de) 2006-05-11
JP2004535463A (ja) 2004-11-25
CA2450915A1 (en) 2003-01-30
US6949548B2 (en) 2005-09-27

Similar Documents

Publication Publication Date Title
DE60022021D1 (de) Zubereitungen enthaltend Apomorphin und Sildenafil und ihre Verwendung zur Behandlung von erektiler Dysfunktion
CY1118849T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
EA200600820A1 (ru) Способы лечения, модификации и устранения боли с использованием 1-оксо-2-(2,6-диоксопиперидин-3-ил)-4-метилизоиндолина
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
SE0002754D0 (sv) New pharmaceutical combination formulation and method of treatment with the combination
WO2004039325A3 (en) Treatment of pain with jnk inhibitors
BG104797A (en) Use of dexmedetomi dine for sedative effect in patients in an intensive care unit
ATE297732T1 (de) Kombinationstherapie zur behandlung von herzinsuffizienz
AR037524A1 (es) Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
NO20055531L (no) Preparat for forbedret kognisjon og hukommelse
ATE306267T1 (de) Kombinationsbehandlung bei akutem myokardinfarkt
SE9902597D0 (sv) New use
ATE487480T1 (de) Perhexilin zur behandlung von chronischer herzinsuffizienz
WO2001080895A3 (en) Methods and compositions for the treatment of cardiac indications
EA200500427A1 (ru) Способы лечения пациентов, страдающих синдромом усталых ног или связанными с ним заболеваниями
ATE464051T1 (de) Kombination aus levosimendan und einer kalziumquelle zur behandlung von herzinsuffizienz
DK1143976T3 (da) Beta-D-2', 3'-didehydro-2', 3'-dideoxy-5-fluorcytidin til anvendelse i behandlingen af HIV-infektioner
DK1265629T3 (da) Anvendelse af væksthormon i lav dosis
Fish Maxillary and Mandibular Neuralgia
BROOKE Finally, it would be interesting to know what proportion of Dr. Irvine's series of gastrectomies these 24 cases provide.-I am, etc.,-
NO20043774L (no) The use of devazenide as analgesic agent
CO5170404A1 (es) Terapia para melanomas
TH54363A (th) วิธีและสารผสมที่ใช้ (-) นอร์ซิสแอไพรด์ร่วมกับตัวยับยั้งบั๊มพ์ของโปรตอนหรือแอนทากอนิสท์ของตัวรับ h2
UA37370A (uk) Спосіб прогнозування ефективності монотерапії антагоністами кальцію під час лікування гіпертонічної хвороби
TH51665A (th) ยาเวชภัณฑ์

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1408977

Country of ref document: EP

EEIH Change in the person of patent owner